Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.
about
Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaThe BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrenceIntegrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomasMolecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules.Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancerThe prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancerPrognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision.Hyperparathyroid genes: sequences reveal answers and questions.A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsyDeregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.New therapies for dedifferentiated papillary thyroid cancerLaser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysisExpression of Notch 1 receptor associated with tumor aggressiveness in papillary thyroid carcinoma.Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse modelRNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.Association Study of FOS-Like Antigen-2 Promoter Polymorphisms With Papillary Thyroid Cancer in Korean Population.Analysis of BRAF(V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies.CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma.Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.Radiation signatures in childhood thyroid cancers after the Chernobyl accident: possible roles of radiation in carcinogenesis.Bioinformatics analyses of significant prognostic risk markers for thyroid papillary carcinoma.Selective use of vandetanib in the treatment of thyroid cancer.Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells.MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.The role of molecular diagnostic testing in the management of thyroid nodules.In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells.Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma.RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study.Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma.Follicular Variant of Papillary Thyroid Carcinoma: Hybrid or Mixture?Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells.Molecular signatures of a disturbed nasal barrier function in the primary tissue of Wegener's granulomatosis.Upregulated LAMB3 increases proliferation and metastasis in thyroid cancer.Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas.BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma.
P2860
Q26853261-B43D7D4D-3620-442C-B022-24305D769E21Q27852737-CFAC1A19-D20C-4449-AAB0-F212E2B2EDDCQ28075975-CF444740-A7F8-4FFC-AE39-198BFB389985Q28475549-1AEB7CEE-4198-410D-A340-DFADAC4A1DA1Q33782114-22F00BB6-1343-491C-998D-6DD59852644DQ33782121-35C7694D-5BA2-4617-957A-4D274C91DAECQ33973118-C1E45C9C-9828-4C4E-A4EA-1C7F5C3F2767Q34331391-F9F16F72-10B4-4CCB-9EA3-071970ED7187Q34628063-7523596B-A9A1-4CD4-97BC-AAF4C4D0214CQ34644257-282BE380-77C3-4343-8E64-4D2FB5D5C77EQ35217023-620652A7-1EC5-47B1-82C0-1AB8F39E4190Q35381593-B1A34CE0-82A1-449F-B2B9-9469824B9751Q35501424-07108BD3-F25C-47D7-A8F6-62EDF64FF466Q35692478-EF0B06D5-8BA9-4ECA-93F0-5B89C2EC252DQ36442403-D6B47618-CA09-4858-96BA-909832FA88DBQ36710074-612D76B0-EBE4-495F-A0B2-3ABEC98580F7Q37205853-3C5A4056-84B1-49D3-B976-EAE688998060Q37554783-1FD79B53-645F-4EE9-B29B-81F111838564Q37598727-EBA0094F-39A3-41E4-BE65-7500F3316CBFQ37621631-290155EE-3CB1-4691-BD2B-A163FEBA5925Q37708464-F9192CAD-3A12-420A-8AC5-1D82C6C5843EQ38214480-573F85EF-3D4F-41AE-B432-D2544000C132Q38284743-97F8C743-785D-4CF2-90D3-96B987C15B46Q38463937-92FD5106-6595-46DE-BD4B-C9BF3F7F945EQ38546474-7800DEA0-DECB-49E7-96C9-D5CC5E65D8DDQ38842231-2919CFF8-0544-41BE-8684-656E850F971CQ39179286-E43EF749-C1EE-4F50-8E09-E8D003CED0E5Q39250953-6FFD0A20-6C7D-4E1D-B401-00C0F61F1287Q39330634-6CABE35A-7924-40D3-8F30-87F13B467B02Q39354316-F0861DD4-5EAB-4E18-8566-D389F42F8926Q39838749-54D5AFCC-D1B7-47D7-8CE0-553D22E3DAF0Q40257700-566ECBFD-F524-464A-9C7D-C529514D1D99Q40636237-33178B35-23DA-4B8F-BE63-1984A7B95E95Q41260523-EC1E9ED6-7534-4C04-A396-9038556D1F73Q41881218-A9FF21ED-C7DB-4F7A-BFF1-5293DE86A65FQ42370484-ED6437E1-66D6-4C6E-B3DA-89D9A6A52628Q46277821-E07E4FE8-AC1F-470C-BF09-629AE339E1D4Q47298385-F00DF07C-6D92-49DE-89F9-16A9236BB50EQ49197249-35CF7C33-ACF6-4DDE-B629-69CCDDBA2909Q50882606-CA6D28A7-F013-4D42-AA33-3A4B49217457
P2860
Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular prognostic markers i ...... status and future directions.
@en
Molecular prognostic markers i ...... status and future directions.
@nl
type
label
Molecular prognostic markers i ...... status and future directions.
@en
Molecular prognostic markers i ...... status and future directions.
@nl
prefLabel
Molecular prognostic markers i ...... status and future directions.
@en
Molecular prognostic markers i ...... status and future directions.
@nl
P50
P1476
Molecular prognostic markers i ...... status and future directions.
@en
P356
10.1016/J.MCE.2010.01.007
P577
2010-02-04T00:00:00Z